fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Indomethacin – dual antiviral and anti-inflammatory for covid-19?

Written by | 17 Jun 2020

Interview and article by Christine Clark. Indomethacin has both anti-inflammatory and anti-viral properties and it could help to hasten recovery from covid-19 infection Indomethacin, if given early to… read more.

Soleno Therapeutics announces top-line results from phase III trial of DCCR for treatment of Prader-Willi syndrome.

Written by | 14 Jun 2020

Soleno Therapeutics, Inc. announced top-line results from the Company’s Phase III trial, DESTINY PWS (C601), evaluating once-daily Diazoxide Choline Controlled Release (DCCR) tablets for patients with Prader-Willi Syndrome… read more.

Johnson & Johnson initiates Phase I/IIa trial of Ad26.COV2-S, recombinant, to treat COVID-19.

Written by | 12 Jun 2020

Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/IIa first-in-human clinical trial of its investigational SARS-CoV-2 vaccine,… read more.

Johnson & Johnson initiates Phase I/IIa trial of Ad26.COV2-S, recombinant, to treat COVID-19.

Written by | 12 Jun 2020

Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/IIa first-in-human clinical trial of its investigational SARS-CoV-2 vaccine,… read more.

Fulcrum Therapeutics to evaluate losmapimod in Phase III trial as a potential treatment for COVID-19.

Written by | 11 Jun 2020

Fulcrum Therapeutics, Inc. announced plans to evaluate losmapimod as a potential treatment for patients with COVID-19 . Fulcrum has submitted an investigational new drug (IND) application to support… read more.

Gilead Sciences files MAA for remdesivir at the EMA to treat COVID-19.

Written by | 9 Jun 2020

The European Medicines Agency (EMA) reports that Gilead Sciences has submitted its marketing application seeking conditional approval of antiviral remdesivir for the treatment of COVID-19. Since the EU… read more.

CE Mark for OPTI SARS-CoV-2 RT-PCR laboratory test kit for the detection of SARS-CoV-2,.- Opti Medical Systems

Written by | 9 Jun 2020

OPTI Medical Systems, Inc., a subsidiary of IDEXX Laboratories, Inc. announced that it has received the CE mark certification in the European Union for its OPTI SARS-CoV-2 RT-PCR… read more.

Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients .- AstraZeneca

Written by | 7 Jun 2020

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved clinical outcomes of patients with severe COVID-19… read more.

RECOVERY trial shows no benefit from hydroxycholoroquine as treatmant for COVID-19.- Novartis

Written by | 7 Jun 2020

In March 2020 RECOVERY was established as a randomised clinical trial to test a range of potential drugs for COVID-19, including hydroxycholoroquine The trial has proceeded at unprecedented… read more.

Inovio and IVI partner with Seoul National University Hospital to start phase 1/II clinical rial of Inovio’s COVID-19 DNA vaccine (INO-4800) in South Korea.

Written by | 6 Jun 2020

Inovio , the International Vaccine Institute (IVI), and Seoul National University Hospital announced a partnership to start a Phase 1/II clinical trial of INOVIO’s COVID-19 vaccine INO 4800… read more.

Roche’s Elecsys IL-6 test receives FDA Emergency Use Authorisation to help in identifying patients at high risk of severe inflammatory response.

Written by | 6 Jun 2020

Roche announcedy that the FDA has issued an Emergency Use Authorisation (EUA) for the Elecsys IL-6 test. This test measures levels of the biomarker interleukin 6 (IL-6) and… read more.

Hydroxychloroquine does not offer COVID-19 protection after exposure according to University of Minnesota study.

Written by | 5 Jun 2020

A University of Minnesota trial with results published in the New England Journal of Medicine, goes the furthest in answering the question of whether a decades-old, repurposed hydroxychloroquine… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.